One Capital Management LLC Trims Stake in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

One Capital Management LLC lessened its position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 1.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 719,814 shares of the company’s stock after selling 10,129 shares during the quarter. One Capital Management LLC owned approximately 10.33% of Global X Genomics & Biotechnology ETF worth $6,989,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of GNOM. Raymond James Financial Inc. purchased a new stake in shares of Global X Genomics & Biotechnology ETF in the 4th quarter valued at $2,974,000. Flow Traders U.S. LLC acquired a new position in Global X Genomics & Biotechnology ETF during the 3rd quarter worth $936,000. Rockefeller Capital Management L.P. acquired a new position in Global X Genomics & Biotechnology ETF during the 3rd quarter worth $205,000. Corrado Advisors LLC grew its stake in Global X Genomics & Biotechnology ETF by 17.3% during the 4th quarter. Corrado Advisors LLC now owns 75,323 shares of the company’s stock worth $731,000 after purchasing an additional 11,099 shares in the last quarter. Finally, Atria Investments Inc acquired a new position in Global X Genomics & Biotechnology ETF during the 3rd quarter worth $122,000. Hedge funds and other institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Price Performance

GNOM opened at $9.11 on Thursday. The business has a fifty day moving average price of $9.83 and a 200 day moving average price of $10.45. The stock has a market capitalization of $63.50 million, a price-to-earnings ratio of -3.89 and a beta of 1.03. Global X Genomics & Biotechnology ETF has a 12 month low of $8.64 and a 12 month high of $12.20.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.